Seek Returns

BIO.B vs. PFE: Bio-Rad Laboratories vs. Pfizer Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while PFE is classified in Pharmaceuticals.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
Profile ItemBIO.BPFE
NameBio-Rad Laboratories, Inc. Class B Common StockPfizer Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization10.49 billion USD167.52 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateSeptember 21, 1999June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
PFE
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
Total Return (1Y)27.69%28.65%
Total Return (3Y, Annualized)9.13%6.41%
Total Return (5Y, Annualized)-12.33%-3.98%

Risk Profile

Drawdown History

BIO.B
PFE
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Bio-Rad Laboratories (BIO.B) is thinly traded at only 11 — larger orders in the latter may face more price impact or wider spreads, depending on market conditions.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
Volatility (1Y, Annualized)30.96%21.72%
Beta (5Y)1.000.35
Max Drawdown (5Y)-70.74%-58.96%
Avg. Volume (3M)1133.67M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
Sharpe Ratio (1Y)0.741.12
Sortino Ratio (1Y)1.101.73

Profitability

ROE (TTM)

Bio-Rad Laboratories (BIO.B) at 14.27% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for BIO.B.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max
109.18%
Q3
6.23%
PFE
4.47%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO.B) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max
18.05%
PFE
6.34%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Pfizer (PFE) at 33.38% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max
83.12%
PFE
33.38%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
ROE (TTM)14.27%4.47%
ROA (TTM)1.50%5.59%
Net Margin (TTM)39.45%6.34%
Operating Margin (TTM)9.46%33.38%
Gross Margin (TTM)52.19%74.90%

Growth

Revenue Growth

Bio-Rad Laboratories (BIO.B) at 0.65% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
Revenue Growth (YoY)0.65%-1.65%
Revenue Growth (3Y CAGR)-2.68%-14.80%
EPS Growth (YoY)---3.55%
EPS Growth (3Y CAGR)---37.12%

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
PFE
1.42
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max
1.42
PFE
0.71
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
Current Ratio (MRQ)3.181.42
Debt / Equity (MRQ)0.180.71
Net Debt / EBITDA-0.731.97

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO.B) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE
7.30%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Bio-Rad Laboratories (BIO.B) pays no dividend (payout 0.00%).

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE
245.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
Dividend Yield (TTM)0.00%7.30%
Dividend Payout Ratio (TTM)0.00%245.71%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Pfizer (PFE) at 41.99 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max
85.34
Q3
43.46
PFE
41.99
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO.B) at 4.05 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
PFE
2.63
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Pfizer (PFE) at 1.88 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max
13.53
Q3
6.54
Median
3.25
PFE
1.88
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Pfizer (PFE)
MetricBIO.BPFE
P/E Ratio (TTM)10.3641.99
P/S Ratio (TTM)4.052.63
P/B Ratio (MRQ)1.381.88
Free Cash Flow Yield (TTM)2.59%7.76%